Aethlon Medical, Inc. (AEMD) Q3 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call indicates mixed signals. The basic financial performance shows increased revenue but also higher operating losses, resulting in a neutral sentiment. The product development updates, particularly the progression to Cohort 2 in the oncology trial and the potential integration with the SLAMB system, are promising but face regulatory hurdles. Market strategy and expenses reflect positive cost management, though uncertainties remain. The Q&A reveals cautious optimism but lacks concrete data on treatment efficacy, leading to a neutral sentiment overall. Without market cap data, the prediction remains neutral.
Key Financial Performance
Cash Balance Approximately $7 million as of December 31, 2025.
Consolidated Operating Expenses (3 months ended December 31, 2025) Approximately $2.06 million, up $250,000 or 13.6% compared to the same period last year. The increase was primarily due to higher payroll and related costs, partially offset by lower clinical trial expenses and reduced professional fees, mainly from Investor Relations activities.
Operating Loss (3 months ended December 31, 2025) $2.06 million, compared to $1.81 million in the prior year period. The increase in operating loss is attributed to higher operating expenses.
Other Income (3 months ended December 31, 2025) $44,000, slightly lower than the $60,000 recorded in the same quarter last year.
Operating Expenses (9-month period ended December 31, 2025) Decreased significantly to $5.36 million, down $1.98 million or 27% from $7.34 million last year. This improvement reflects lower payroll, general and administrative costs, and professional fees, highlighting the impact of ongoing cost management initiatives.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Hemopurifier platform: Continued enrollment and treatment progress in the Australian oncology trial. Advancement in compatibility with a simplified blood treatment system to expand clinical and commercial flexibility.
Extracellular Vesicle (EV) research: Ongoing expansion of the EV research platform supporting Hemopurifier as a multi-indication therapeutic.
Australian oncology trial: Increased interest and participation due to partnerships with Trialfacts and Dedicated for advertising and prescreening.
Cost management: Operating expenses decreased by 27% year-to-date compared to the prior year, reflecting lower payroll, general and administrative costs, and professional fees.
R&D focus: Exploring Hemopurifier's application in Long COVID and other diseases like lupus, rheumatoid arthritis, and cardiovascular diseases. Research on compatibility with simplified blood treatment systems to broaden usage.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory and Clinical Trial Risks: The Australian oncology trial is still in progress, with safety data pending review by the Data Safety Monitoring Board (DSMB). There is uncertainty regarding whether the trial will advance to the next cohort or require additional participants in the current cohort. This could delay the timeline for trial completion and subsequent regulatory approvals.
Operational and Financial Risks: Operating expenses increased by 13.6% in the most recent quarter compared to the prior year, primarily due to higher payroll and related costs. This increase in expenses, coupled with a limited cash balance of $7 million, could strain financial resources if cost management initiatives are not sustained.
Market and Adoption Risks: The Hemopurifier technology is still under development and has not yet demonstrated widespread clinical or commercial adoption. The success of the technology depends on proving its efficacy and safety in ongoing trials, as well as overcoming potential market resistance to new medical devices.
Technological and R&D Risks: The Hemopurifier's compatibility with simplified blood treatment systems is still under research. Any failure to demonstrate compatibility could limit its usability in oncology units and infusion centers, potentially impacting its market potential.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Australian oncology trial: Targeting late March 2026 for a Data Safety Monitoring Board (DSMB) meeting to review safety data from Cohort 2. Depending on the DSMB's recommendation, the trial may advance to the third and final cohort or require additional patients in the current cohort. The trial aims to determine the number of Hemopurifier treatments needed to decrease extracellular vesicle concentrations and improve immune response against tumor cells.
Hemopurifier compatibility research: Research is ongoing to evaluate the Hemopurifier's compatibility with a simplified blood treatment system (SLAMB system). This system could enable treatments in oncology units and infusion centers without the need for dialysis machines or nephrologists, potentially expanding clinical and commercial flexibility.
Long COVID research: Exploring the Hemopurifier's ability to bind extracellular vesicles (EVs) and decrease microRNAs causing immune dysregulation in Long COVID patients. Future research may investigate other cargo within EVs, such as viral particles, to expand therapeutic applications.
Pipeline expansion: Plans to examine the Hemopurifier's ability to remove platelet-derived EVs and microRNAs in patients with diseases like lupus, rheumatoid arthritis, systemic sclerosis, multiple sclerosis, cardiovascular diseases, sepsis, and ALS. This aligns with the strategy of developing a pipeline within a single device.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:You have moved on to Cohort 2 in the trial. Can you confirm that participants will now receive two Hemopurifier treatments instead of one, but the follow-up period remains the same?
A:Yes, the follow-up period remains the same. Participants in Cohort 2 will receive two Hemopurifier treatments, typically on a Monday and Friday, allowing observation of the kinetics of EV numbers and the effects on T cells.
Q:What would connecting the Hemopurifier to the SLAMB system mean in terms of opening new doors or facilitating its use in different medical centers?
A:The SLAMB system uses a smaller, less invasive single-lumen catheter, which could be placed in the arm instead of the neck. This would simplify the process for hospital staff and patients, making it less invasive and potentially allowing the treatment to be administered in oncology or infusion centers instead of dialysis units.
Q:Does the SLAMB system make the treatment less daunting for patients and simpler for hospital staff?
A:Yes, the SLAMB system would make the treatment less invasive for patients by using smaller catheters and would simplify administration for hospital staff, integrating the treatment into existing therapeutic settings like oncology units.
Q:How are you maintaining cost-effectiveness in your operations, particularly in preclinical research and the Long COVID program?
A:The company is focused on cost containment by obtaining samples at minimal cost, conducting work in-house with a small scientific staff, and limiting the use of outside labs. Despite these measures, they are advancing research, publishing articles, and progressing in the oncology trial.
Q:What is the timeline for treating the third patient in the oncology trial and presenting safety data?
A:The third patient is expected to be treated by the end of February, and the Data Safety Monitoring Board will review safety data by late March. A decision on moving to the third cohort or adding more patients to the second cohort is expected the same day or the next business day after the board meeting.
Q:How quickly can you enroll participants for the third cohort if approved?
A:There is a pool of potential participants already lined up. Once the protocol allows, these participants can be approached for consent, screened, and scheduled for treatment, enabling a quick transition to the third cohort.
Q:Why was the time gap between treatments in the trial set at five days, and could extending this gap be more beneficial?
A:The five-day gap (e.g., Monday and Friday treatments) was informed by prior plasma exchange trials, which suggested 2-3 treatments per week were needed to keep EV numbers down. The trial design aims to determine the optimal frequency and duration of treatments.
Q:Would incorporating the Hemopurifier into the SLAMB system face regulatory hurdles?
A:Yes, the SLAMB system is not yet FDA-approved, and compatibility testing with the Hemopurifier would be required. Additional safety tests and ex vivo experiments would likely be needed before integration.
Q:Are the patients in Cohort 2 the same as those in Cohort 1?
A:No, the patients in Cohort 2 are entirely new and not the same as those in Cohort 1.
Q:Is there a need for Cohort 3, or could the trial conclude with Cohort 2?
A:The need for Cohort 3 depends on the Data Safety Monitoring Board's decision and the data from Cohort 2. Based on prior research, three treatments may be superior to two, so Cohort 3 is likely necessary to fully evaluate efficacy.
Q:Will the SLAMB system integration speed up the current trial?
A:No, the SLAMB system integration is a future consideration and will not impact the current or next trial.
Q:Is there a possibility of resuming clinical trials in India to speed up progress?
A:No, the focus is on completing the trial in Australia. Resuming trials in India would be a distraction and is not planned unless there is an emergency use situation.
Q:Review of Unclear Management Responses
A:Management avoided providing a direct answer regarding the potential regulatory hurdles and timeline for integrating the SLAMB system with the Hemopurifier. They also did not provide specific data or clarity on the efficacy of two treatments in Cohort 2, stating it was premature to comment.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ALS Aethlon
Aethlon Medical
Aethlon device
Aethlon removal
Aethlon uptick
Cohort
Conference
Dedicated
EV
HP treatment
Keytruda
Opdivo
RD
Trialfacts
addition
blood
cohort trial
compatibility
concentration
dialysis machine
end
exclusion
indication
lumen catheter
peer journal
plasma
platform
preprint server
progress oncology
sclerosis
screening
server bioRxiv
system
treatment regimen
trial patient
unit
work
AEMD Transcript
Aethlon Medical, Inc. (AEMD) Q3 2026 Earnings Call Transcript
Unknown2-12
The earnings call indicates mixed signals. The basic financial performance shows increased revenue but also higher operating losses, resulting in a neutral sentiment. The product development updates, particularly the progression to Cohort 2 in the oncology trial and the potential integration with the SLAMB system, are promising but face regulatory hurdles. Market strategy and expenses reflect positive cost management, though uncertainties remain. The Q&A reveals cautious optimism but lacks concrete data on treatment efficacy, leading to a neutral sentiment overall. Without market cap data, the prediction remains neutral.
Aethlon Medical, Inc. (AEMD) Q2 2026 Earnings Call Transcript
Unknown11-12
The earnings call reveals several concerns: limited cash balance raising sustainability doubts, a decision to not proceed with the India trial, and challenges in patient recruitment. Despite reduced expenses, the financial health is precarious. The Q&A section highlights uncertainties in trial outcomes and management's evasive responses, which further dampen sentiment. The combination of these factors suggests a negative outlook for the stock price.
Aethlon Medical, Inc. (AEMD) Q1 2026 Earnings Call Transcript
Unknown8-13
The earnings call highlights several risks and challenges, including regulatory delays, financial constraints, and clinical trial uncertainties. Despite positive preclinical data and cost-saving measures, the company's limited cash balance and operational risks overshadow potential benefits. The Q&A section revealed management's hesitance to provide clear guidance on trial timelines and efficacy, further dampening investor sentiment. The decision to halt the India trial due to regulatory issues adds to the negative outlook. Overall, these factors suggest a negative stock price reaction in the short term.
Aethlon Medical, Inc. (AEMD) Q4 2025 Earnings Call Transcript
Unknown6-26
The earnings call summary shows reduced operating expenses and a maintained cash balance, which are positive. However, the noncash charge and reliance on equity financing are concerns. The Q&A section reveals no significant capital outlay for collaborations and faster patient enrollment, but vague responses on funding and partnerships raise uncertainty. The overall sentiment is neutral due to mixed financial health and unclear future funding plans.
AEMD Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
